Skip to content
TRDAEntrada Therapeutics, Inc.

Earnings

When Entrada Therapeutics, Inc. reports, what it reported each quarter, and how the stock took the results.

27 quarters. Mar 31, 2020 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Feb 25, before the open

Thu, Feb 25, 2027in 99 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Feb 23 – Mar 18

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$1.30M
Revenue, change from a year earlier: Q3 2026 −43.9%, Q2 2026 −53.9%, Q1 2026 −95.7%, Q4 2025 −96.5%
Net income
-$39.16M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026$905.00K−43.9% vs Q3 2025

Latest results

  1. Q3 2026Nov 5, 2026, before the openThe release10.1%by the close of Nov 5
    Revenue
    $905.00K
    −43.9%
    Net income
    -$39.74M
    N/M
    EPS
    -$0.94
    N/M
    Entrada Therapeutics, Inc. (Nasdaq: TRDA) today reported financial results for the third quarter ended September 30, 2026, and highlighted recent business updates.
  2. Q2 2026Aug 5, 2026, before the openThe release2.3%by the close of Aug 5
    Revenue
    $898.00K
    −53.9%
    Net income
    -$42.76M
    N/M
    EPS
    -$1.01
    N/M
  3. Q1 2026May 7, 2026, before the openThe release57.0%by the close of May 7
    Revenue
    $875.00K
    −95.7%
    Net income
    -$39.72M
    N/M
    EPS
    -$0.95
    N/M
  4. Q4 2025Feb 26, 2026, before the openThe release+6.4%by the close of Feb 26
    Revenue
    $1.30M
    −96.5%
    Net income
    -$39.16M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 5, 2026 · pre-marketNov 5, 202636 d10-Q$905.00K−43.9%-$0.9410.1%
Q2 2026Jun 30, 2026Aug 5, 2026 · pre-marketAug 5, 202636 d10-Q$898.00K−53.9%-$1.012.3%
Q1 2026Mar 31, 2026May 7, 2026 · pre-marketMay 7, 202637 d10-Q$875.00K−95.7%-$0.9557.0%
FY 2025
Q4 2025derivedDec 31, 2025Feb 26, 2026 · pre-marketFeb 26, 202657 d10-K$1.30M−96.5%—+6.4%
Q3 2025Sep 30, 2025Nov 6, 2025 · pre-marketNov 6, 202537 d10-Q$1.61M−91.8%-$1.06+1.4%
Q2 2025Jun 30, 2025Aug 6, 2025 · pre-marketAug 6, 202537 d10-Q$1.95M−97.9%-$1.04+2.3%
Q1 2025Mar 31, 2025May 8, 2025 · pre-marketMay 8, 202538 d10-Q$20.56M−65.2%-$0.42+5.7%
FY 2024
Q4 2024derivedDec 31, 2024Feb 27, 2025 · pre-marketFeb 27, 202558 d10-K$37.40M−10.6%—+0.5%
Q3 2024Sep 30, 2024Nov 5, 2024 · pre-marketNov 5, 202436 d10-Q$19.57M−55.3%-$0.35+4.8%
Q2 2024Jun 30, 2024Aug 13, 2024 · pre-marketAug 13, 202444 d10-Q$94.69M+421.2%$1.55+14.4%
Q1 2024Mar 31, 2024May 7, 2024 · pre-marketMay 7, 202437 d10-Q$59.12M+134.0%$0.68+6.4%
Earlier years, FY 2020 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 5, 2026000064
10-QAug 5, 2026000054
10-QMay 7, 2026000028
10-KFeb 26, 2026000011
10-QNov 6, 2025000050
10-QAug 6, 2025000043
10-QMay 8, 2025000024
10-KFeb 27, 2025000011
10-QNov 5, 2024000063
10-QAug 13, 2024000047

Provenance

ProvenanceData status and checks

Entrada Therapeutics, Inc. · CIK 1689375 · Engraved from SEC EDGAR